The Inflammasome NLRP3 as a Novel Therapeutic Target for Idiopathic Pulmonary Fibrosis (IPF)

The authors review evidence of NOD-like receptor (NLR) P3 activation in IPF, of NLRP3 inhibition in different animal models of fibrosis, and highlight the recent advances in direct and indirect NLRP3 inhibitors.